Get the Stockscreener App
11.09
1.46%
0.16
Pre-market:
11.13
0.04
+0.36%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $11.09, with a volume of 9.32M.
It is up +1.46% in the last 24 hours and up +9.58% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$10.93
Open:
$10.99
24h Volume:
9.32M
Relative Volume:
1.02
Market Cap:
$12.77B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-3.4984
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
+3.64%
1M Performance:
+9.58%
6M Performance:
+27.32%
1Y Performance:
-12.81%
1-Day Range:
$10.94
$11.29
1-Week Range:
$10.64
$11.29
52-Week Range:
$6.85
$13.13
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
11.09 | 12.59B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
118.16 | 52.29B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.22 | 44.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.40 | 42.39B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.33 | 32.65B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
479.51 | 21.07B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Generic Drugs Market to Reach US$ 942.69 Billion by 2033 at 7.1% - openPR.com
CAM, Khaitan act on Biocon Limited acquiring stake in Biocon Biologics from Serum, Viatris - Bar and Bench
Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛
Viatris Sells Biocon Biologics Stake for $815 Million - TipRanks
Viatris Inc Announces Agreement to Monetize Biocon Biologics Stake - TradingView
Viatris to Sell its Equity Stake in Biocon Biologics for $815 Million - marketscreener.com
Viatris signs agreements with Biocon on $815m stake sale - Yahoo Finance
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal (VTRS:NASDAQ) - Seeking Alpha
Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln - Nasdaq
Oculis (Nasdaq: OCS) accelerates Privosegtor into registrational optic neuropathy trials - Stock Titan
Biocon To Absorb Biocon Biologics, Pursue Rs 4,500 Cr QIP To Fund Viatris Payout - BW Businessworld
Biocon to absorb biologics unit, eyes Rs 4,500 cr fund raise to buy Viatris’s residual stake - Moneycontrol
Biocon integrates Biocon Biologics; to raise ₹4,500 crore via QIP to fund Viatris payout - BusinessLine
Viatris shareholders elect directors and approve proposals at annual meeting By Investing.com - Investing.com Nigeria
Viatris Holds Annual Shareholder Meeting on December 5 - TipRanks
Viatris shareholders elect directors and approve proposals at annual meeting - Investing.com India
Mark Cuban Takes Aim at FDA Fees - GuruFocus
Why Viatris Inc. (VIA) stock trades below fair valueJuly 2025 Pullbacks & Weekly Top Gainers Alerts - Newser
Mark Cuban calls for end to generic drug application fees to boost domestic manufacturing - Seeking Alpha
Can Viatris Inc. (VIA) stock survive global slowdownWall Street Watch & Free Daily Entry Point Trade Alerts - Newser
Can Viatris Inc. (VIA) stock surprise markets with earningsTrade Volume Summary & Low Drawdown Momentum Ideas - Newser
What is the fair value estimate for Viatris Inc. (VIA) stock in 2025Weekly Stock Analysis & AI Based Buy/Sell Signal Reports - Newser
Why Viatris Inc. (VIA) stock is a must watch tickerJuly 2025 Patterns & Risk Controlled Daily Plans - Newser
Is Viatris Inc. (VIA) stock a good hedge against inflationMarket Growth Summary & Stock Portfolio Risk Management - Newser
How Viatris Inc. stock benefits from global expansion2025 Top Gainers & High Conviction Investment Ideas - Newser
Will Viatris Inc. (VIA) stock extend growth storyMarket Risk Summary & Risk Managed Investment Strategies - Newser
How Viatris Inc. (VIA) stock compares with market leadersWeekly Stock Report & Step-by-Step Swing Trade Plans - Newser
Viatris Inc.: Revenue and Earnings Analysts Forecasts Revisions | VTRS | US92556V1061 - marketscreener.com
Viatris Inc.: Target Price Consensus and Analysts Recommendations | VTRS | US92556V1061 - marketscreener.com
Viatris Inc.: Financial Data Forecasts Estimates and Expectations | VTRS | US92556V1061 - marketscreener.com
Viatris Inc.: Dividend historical data and projections - marketscreener.com
What market sentiment indicators show for Viatris Inc. (VIA) stockJuly 2025 Big Picture & Technical Buy Zone Confirmations - Newser
Behavioral Patterns of VTRS and Institutional Flows - news.stocktradersdaily.com
Levi & Korsinsky Notifies Viatris Inc. (VTRS) Shareholders of Class Action Lawsuit and June 3, 2025 Deadline - The National Law Review
VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
How Viatris Inc. (VIA) stock trades after earningsMarket Rally & Risk Controlled Stock Pick Alerts - moha.gov.vn
Non-operating income (total) of Viatris, Inc. – SIX:VTRS - TradingView
Viatris Inc. (VIA.DE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Shareholders That Lost Money on Viatris Inc. (VTRS) Should Contac - The National Law Review
These 10 S&P 500 Stocks Are Dirt Cheap This Black Friday - Benzinga
Merz Loses Bid To Block Viatris In Unified Patent Court - Law360
What Do Recent Portfolio Streamlining Moves Mean for Viatris’s True Value in 2025? - Yahoo Finance
Merz fails with PI request in first ever SPC case against Viatris - JUVE Patent
Fondaparinux Market Set to Significantly Grow from 2025 to 2032 | - openPR.com
Viatris to Participate in Upcoming Investor Conferences - Finviz
Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know - The Globe and Mail
Is Viatris Inc. (VIA) stock inflation resilientJuly 2025 Price Swings & Verified Trade Idea Suggestions - newser.com
Can Viatris Inc. (VIA) stock sustain double digit ROETrade Risk Report & Long-Term Safe Investment Plans - newser.com
Can Viatris Inc. (VIA) stock test all time highsJuly 2025 Sector Moves & Fast Exit Strategy with Risk Control - newser.com
(VTRS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Ex-Dividend Reminder: Viatris, Radian Group and Equitable Holdings - Nasdaq
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):